Somya Rakshit, a 30-year-old from Lucknow with congenital heart disease and two open-heart surgeries, successfully climbed ...
Stocktwits on MSN
Moderna Stock Slides After-Hours On CMV Vaccine Failure In Phase 3 Trial — Retail Traders Warn Of ‘Endless’ Cash Burn
Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a large Phase 3 trial, prompting the company to end its congenital CMV program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback